The Stanford University School of Medicine and Santa Clara Valley Medical treated the fifth patient in the Geron Corp. sponsored trial of a human embryonic-stem-cell-derived treatment for spinal cord injury on Nov. 16th.
Humans may need longer than a year to show results. It was shown that primates require more time than rats to recuperate.
Phase I results for GRN1005, Geron found the peptide/paclitaxel conjugate to be generally well tolerated. Since paclitaxel itself is an approved product, this is good news. Geron plans to initate two Phase II clinical trials for GRN1005 soon [December 2011] with data to become available in the first half of 2013. With good results it will most likely be fast tracked.
ACTC is in two Phase 1/2 trials, which injects embryonic stem cells into the eye, one for Stargardt's Macular Dystrophy and Dry Age Related Macular Degeneration. Interesting news, patients want their second eye injected. That's a very strong indication that they are experiencing improvement. The studies are notable because Catholic nuns are among the patients. That is wild.
I'm long Geron and ACTC.
Good luck is this rigged casino,
No comments:
Post a Comment